Risk classification of life and health insurance applicants with atypical melanocytic hyperplasia or malignant melanoma in situ

Richard Wagner, C. M. Murphy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Physicians may attempt to disguise malignant melanoma in situ from insurance companies by diagnosing atypical melanocytic hyperplasia instead. This study indicates that the insurance industry is not misled by atypical melanocytic hyperplasia and treats it equivalently to malignant melanoma in situ. In addition, physicians' failure to diagnose malignant melanoma in situ may result in underestimation of the incidence of malignant melanoma and may cause inadequate initial treatment and patient follow-up.

Original languageEnglish (US)
Pages (from-to)352-354
Number of pages3
JournalCutis
Volume50
Issue number5
StatePublished - 1992

Fingerprint

Life Insurance
Health Insurance
Hyperplasia
Melanoma
Insurance
Physicians
Industry
Incidence

ASJC Scopus subject areas

  • Dermatology
  • Immunology and Allergy

Cite this

Risk classification of life and health insurance applicants with atypical melanocytic hyperplasia or malignant melanoma in situ. / Wagner, Richard; Murphy, C. M.

In: Cutis, Vol. 50, No. 5, 1992, p. 352-354.

Research output: Contribution to journalArticle

@article{a60bb745e96a4ce1ae65cc462adb73f9,
title = "Risk classification of life and health insurance applicants with atypical melanocytic hyperplasia or malignant melanoma in situ",
abstract = "Physicians may attempt to disguise malignant melanoma in situ from insurance companies by diagnosing atypical melanocytic hyperplasia instead. This study indicates that the insurance industry is not misled by atypical melanocytic hyperplasia and treats it equivalently to malignant melanoma in situ. In addition, physicians' failure to diagnose malignant melanoma in situ may result in underestimation of the incidence of malignant melanoma and may cause inadequate initial treatment and patient follow-up.",
author = "Richard Wagner and Murphy, {C. M.}",
year = "1992",
language = "English (US)",
volume = "50",
pages = "352--354",
journal = "Cutis",
issn = "0011-4162",
publisher = "Quadrant Healthcom Inc.",
number = "5",

}

TY - JOUR

T1 - Risk classification of life and health insurance applicants with atypical melanocytic hyperplasia or malignant melanoma in situ

AU - Wagner, Richard

AU - Murphy, C. M.

PY - 1992

Y1 - 1992

N2 - Physicians may attempt to disguise malignant melanoma in situ from insurance companies by diagnosing atypical melanocytic hyperplasia instead. This study indicates that the insurance industry is not misled by atypical melanocytic hyperplasia and treats it equivalently to malignant melanoma in situ. In addition, physicians' failure to diagnose malignant melanoma in situ may result in underestimation of the incidence of malignant melanoma and may cause inadequate initial treatment and patient follow-up.

AB - Physicians may attempt to disguise malignant melanoma in situ from insurance companies by diagnosing atypical melanocytic hyperplasia instead. This study indicates that the insurance industry is not misled by atypical melanocytic hyperplasia and treats it equivalently to malignant melanoma in situ. In addition, physicians' failure to diagnose malignant melanoma in situ may result in underestimation of the incidence of malignant melanoma and may cause inadequate initial treatment and patient follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0026492850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026492850&partnerID=8YFLogxK

M3 - Article

C2 - 1468256

AN - SCOPUS:0026492850

VL - 50

SP - 352

EP - 354

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 5

ER -